Anavex Life Sciences Corp (AVXL)

[flsh56]

I am shocked, shocked that Avanex has run into a delay initiating the trials...

Who knew that pioneering a promising new scientific approach to diseases that big pharma has failed and failed again, even recently abandoning the space, alongside a paradigm shift in clinical trials targeting a precision design which will change the face of all future clinical trials, even strongly predicting the outcome of later stage trials, and advancing such through new (but previously 2017 expected) CNS guidelines from the FDA which now finally released would seem to fit exactly into the Anavex wheelhouse, would run into such challenges!

The market has justly as one would expect in old school thinking, with the whirlwind of uncertainty created which leads you to question everything, and in its most volatile way punished the share price for running into these challenges. Perhaps, and in my own humble opinion, the market has no clue how to value the Anavex platform. Perhaps the picture will become clearer on the initiation of the Rett trial which I believe, with the agency endorsement, will potentially reveal the challenges that were incurred.

I am sure Missling needs to tread these uncharted waters very carefully especially with the FDA...

Someone posted Maxim changed their price target to 5 dollars. I will welcome that in the 2nd quarter on the start of the Rett trial. They will have the opportunity to revise upwards in 2018.

Some posts here and on other message boards would have you think that Missling has duped the MJFF, The Australian Government and even the young children's money of the Rett org. How preposterous!

This long is just patiently waiting for multiple executions in the revised plan timelines (this change, in reality can be considered only a few months, a quarter or two, not very long in the evolution of medicine) and the reversal here can be quite dramatic...